Pancreatic Cancer Research

ResearcherNational Sun Yat-sen UniversityActive in the last 2 years

Ching‐Chung Ko

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0721-9606; OpenAlex author ID A5018885199. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 4

  1. Integrin αvβ3-dependent pathogenic effect and therapeutic effects of DL-N2 combined with EGFR inhibitors in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12967-026-07865-0↗
  2. Hypoxia-induced MIR31HG expression promotes partial EMT and basal-like phenotype in pancreatic ductal adenocarcinoma based on data mining and experimental anal… Co-author DOI 10.1186/s12967-025-06292-x↗
  3. Dasatinib inhibits PD-L1 expression via a proteasomal pathway in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.7150/jca.124262↗
  4. Long Non-Coding RNA MIR31HG Promotes the Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma Cells. Co-author DOI 10.3390/ijms23126559↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pei‐Ming Yang · 3 shared papers, 2022–2025 · strength 1.22
  2. Yao‐Yu Hsieh · 1 shared paper, 2022 · strength 0.26
  3. Jaqueline Whang-Peng · 1 shared paper, 2026 · strength 0.22
  4. Zilin Li · 1 shared paper, 2026 · strength 0.22
  5. Dahlak Daniel Solomon · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.